Skip to main content

Psoriatic arthritis

P2 Trial: DEU in PsA Encouraging results for DCV 6 and 12 mg qd. ACR20 63% for DCV 12 mg (p=0.0004) Not yet FDA approved for PsA, only PsO Pending P3 P2: DEU in SLE - PAISLEY Improved SRI(4), CLASI-50 at w32 Merola #RNL2025 @RheumNow https://t.co/RV7OPaZWjx
Eric Dein @ericdeinmd( View Tweet )
Combination therapy in PsA . Regulatory and reimbursement issues may inhibit such strategies (and potential adverse event concerns) but anecdotal evidence would suggest a role in difficult to treat cases. @RheumNow #RNL2025 https://t.co/IIoUiJyP95
Richard Conway @RichardPAConway( View Tweet )
#HOT #topic Will #Rx of #PsO PREVENT onset of #PsA Well, maybe 🤔 Alexis R Ogdie ⁦@RheumNow⁩ #RNL2025 70% of #psoriatic #arthritis is preceded by #psoriasis Still a bit of a debate re prevention of PsA https://t.co/7bce8kcjdr
Janet Pope @Janetbirdope( View Tweet )
Risk factors for development of PsA in psoriasis. Psoriasis severity, obesity, and depression. @alexisogdie @RheumNow @RNL2025 https://t.co/obMDBvLLnx
Richard Conway @RichardPAConway( View Tweet )
Great graph from @AlexisOgdie on the effect of biologic treatment on PsA development in psoriasis. Obvious front-loading in those who need systemic therapy. But over time those who don't appear to develop more PsA @RheumNow @RNL2025 https://t.co/UxUZyKb0NA
Richard Conway @RichardPAConway( View Tweet )
Can treatment of PsO prevent PsA? -Severity of PsO and obesity->Risk fx for PsA -PRESTO scores: Predicts whether you will develop PsA in the next year vs next 5 years -Does ttx of PsO impact development of PsA? Trials are mostly observational (several confounders) TriNetX data:… https://t.co/TBv3Y2TLZv https://t.co/1K0MtMQ5gn
Adela Castro @AdelaCastro222( View Tweet )
Predicting #PsA PRESTO study #obvious risks are #predictive Alexis R Ogdie ⁦@RheumNow⁩ #RNL2025 bad PsO 2X ^PsA High BMI Depression Modifiable risks #psoriasis #psoriatic #arthritis https://t.co/pOxidCWcg5
Janet Pope @Janetbirdope( View Tweet )
QD Clinic - New Palmoplantar Psoriasis and PsA New Onset Palmoplantar PsO and PsA - what are the options? Features Dr. Jack Cush. QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025 Register at https://t.co/2dcFVgu8z6https://t.co/3ubBL6HVGF https://t.co/Zdd6Dih5eZ
Dr. John Cush @RheumNow( View Tweet )

Drug Naming Games (2.7.2025)

Dr. Jack Cush reviews the news, regulatory and journal reports from the past week on RheumNow.com.

Read Article

Granzyme - a major driver of inflammatory & autoimmune diseases

EurekAlert!

Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is the complement system—a group of proteins that patrols our body, ever vigilant for signs of infection or injury. Now, over 100 years after the

Read Article
Is IL-23i better than IL-17i at lowering PsA risk? Retrospective, real-world EHR data study from TriNetX shows that among 4580 adult psoriasis pts (2,273 on IL23i vs 2,307 on IL17i), IL23i had signif lower PsA incidence (HR 0.60; 0.44–0.82, P 0.001), esp if 41-65 yrs (HR 0.42) &… https://t.co/ZuCAiOTIke https://t.co/8PkDCugYy0
Dr. John Cush @RheumNow( View Tweet )
QD Clinic - New Palmoplantar Psoriasis and PsA New Onset Palmoplantar PsO and PsA - what are the options? Features Dr. Jack Cush. QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025 Register at https://t.co/2dcFVgu8z6https://t.co/HZZuDvga58 https://t.co/wWKhnIECwB
Dr. John Cush @RheumNow( View Tweet )
Study of 702 pts who transitioned from PsO to PsA (median 9yrs) - no baseline differences in PsA pts who transitioned late (>9yrs); but on follow-up, the late group had lower Dz activity, less csDMARD use, but no difference in radiographic progression https://t.co/xUPXA79weS https://t.co/eUeemqovv8
Dr. John Cush @RheumNow( View Tweet )
Participation is Up! (1.31.2025) Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow. We also have two call-in cases on "Ask Cush Anything". https://t.co/kxMkDW5X8c https://t.co/AjIuNzk7co
Dr. John Cush @RheumNow( View Tweet )
NIH study of MSK disease burden finds research on neck pain as most underfunded (0.83%) followed by LBP (13.9%), OA (35.1%) & RA (66.3%) - NIAMS is low compared to other institutes. In USA, MSK dz affect 1 in 3 people, approximately 127.4 million individuals.… https://t.co/MqU9TsY6GR https://t.co/rRvUYc2yee
Dr. John Cush @RheumNow( View Tweet )
North American Real-world EHR data of PsA & axSpA pts (n 2200 Ea.) found no higher rates of CVD (acute MI, CVA or revascularization) or solid cancers (breast, colorectal, lung, prostate) when comparing JAKi to either TNFi or IL-17i use (over 3 years). https://t.co/macjpWxdnY https://t.co/9gXiomU3YD
Dr. John Cush @RheumNow( View Tweet )

Adalimumab Withdrawal in Uveitis Patients

Adalimumab is an effective treatment for JIA-associated uveitis and has been FDA approved for such use - but for how long and can the drug be withdrawn? An adalimumab (ADA) withdrawal trial has shown recurrence of uveitis, arthritis, or both, when the disease was previously controlled on ADA.

Read Article
Head-to-Head Clinical Trials https://t.co/kLwVKRcnna https://t.co/XDhk9VAIin
Dr. John Cush @RheumNow( View Tweet )

Cardiovascular Risk in Cutaneous Lupus Erythematosus

A retrospective study of cutaneous lupus erythematosus (CLE) patients finds an increased risk of atherosclerotic cardiovascular disease (ASCVD) on par with systemic lupus patients.

An IBM MarketScan Commercial Claims data analysis from 2018 to 2020 included

Read Article
QD Clinic - Natural RA PsO/PsA patient avoiding DMARDs and Biologics, and wants Natural therapies Features Dr. Jack Cush QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025 Register at https://t.co/2dcFVgu8z6 https://t.co/nYhcPaC0qW https://t.co/wT80JoY4OE
Dr. John Cush @RheumNow( View Tweet )
Childhood Maltreatment and the Risk of Rheumatic Diseases A UK retrospective matched open cohort study shows that children who suffered from abuse, neglect or domestic abuse carry a significantly increased risk of developing rheumatoid arthritis or psoriasis in later life.… https://t.co/f0XMDJbvvg https://t.co/9KvpixsNFL
Dr. John Cush @RheumNow( View Tweet )
Network metanalysis of 9 RCTs, 3699 patients looked at small molecule Rx in #PsA. With ACR 50/70, PASI 75, & HAQ-DI @ wk 12-16, UPA was > ADA in PASI75 (RR 1.2); Deucravacitinib > Otezla at HAQ (RR −0.16) no OTHER SIGNIF differences observed https://t.co/WQCFQDnnft https://t.co/7NTNIpzEuG
Dr. John Cush @RheumNow( View Tweet )

Fallen Angels (1.17.2025)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com; and pays homage to colleagues who passed away in 2024.

Read Article

Childhood Maltreatment and the Risk of Rheumatic Diseases

EurekAlert!

A UK retrospective matched open cohort study shows that children who suffered frmo abuse, neglect or domestic abuse carry a significantly increased risk of developing rheumatoid arthritis or psoriasis in later life.    

Researchers used Dexter software and over 16 million

Read Article
Network metanalysis of 9 RCTs, 3699 patients looked at small molecule Rx in #PsA. With ACR 50/70, PASI 75, & HAQ-DI @ wk 12-16, UPA was > ADA in PASI75 (RR 1.2); Deucravacitinib > Otezla at HAQ (RR −0.16) no OTHER SIGNIF differences observed https://t.co/T0eMkXrxQX https://t.co/FCkbuhi1ze
Dr. John Cush @RheumNow( View Tweet )
×